FDA Drug information

Bendamustine hydrochloride

Up to date, easily accessible information about drugs approved by the US Food & Drug Administration (FDA)

Bendamustine Hydrochloride BENDAMUSTINE HYDROCHLORIDE 100 mg/1 Apotex Corp
Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100 mg/20mL BluePoint Laboratories
Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100 mg/20mL BluePoint Laboratories
BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 100 mg/20mL Eugia US LLC
Bendamustine Hydrochloride BENDAMUSTINE HYDROCHLORIDE 25 mg/1 Apotex Corp
Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 25 mg/5mL BluePoint Laboratories
Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 25 mg/5mL BluePoint Laboratories
BENDAMUSTINE HYDROCHLORIDE BENDAMUSTINE HYDROCHLORIDE 25 mg/5mL Eugia US LLC
Bendamustine Hydrochloride BENDAMUSTINE HYDROCHLORIDE 25 mg/mL Apotex Corp

Learning Zones

Learning Zone Homepage

Advances in HS

30 mins

Learning Zone

All Things Angioedema and Urticaria: Podcasts

30 mins

3d rendered medically accurate illustration of a womans large intestine

Learning Zone Homepage

Ulcerative colitis Learning Zone

90 mins

Learning Zone Homepage

Psoriasis Academy

910 mins

Learning Zone Homepage

Alopecia areata Learning Zone

60 mins

Responding to unmet needs for metastatic castration-resistant prostate cancer

Learning Zone Homepage

mCRPC in focus

110 mins

Pediatric Eosinophilic Esophagitis teaser image

Learning Zone

Type 2 Inflammation in Gastroenterology

160 mins

Learning Zone Homepage

Pediatric Atopic Dermatitis

30 mins

Myocardium Cardiac muscle fibers banner image

Learning Zone Homepage

Pompe Disease: Key findings from WMS 2022

150 mins

Learning Zone Homepage

Biomarker innovation in Alzheimer’s disease Learning Zone

60 mins

Learning Zone Homepage

Supportive care in oncology Learning Zone

150 mins

Learning Zone Homepage

Albumin in fluid management Learning Zone

115 mins

Learning Zone Homepage

Glaucoma Learning Zone

190 mins

Image of AI generated blood clot formation that would require pharmacological treatments available for various vascular conditions, such as anticoagulants, anti platelet agents, and vasodilators

Learning Zone Homepage

Antiplatelet therapy in ACS: Choices and Controversies

270 mins

patient receiving dialysis, hospital image

Learning Zone Homepage

Chronic Kidney Disease Learning Zone

340 mins

Homepage_HS_Patient and doctor speaking_ Teaser image

Learning Zone Homepage

Hidradenitis suppurativa

220 mins

Learning Zone Homepage

Chronic Spontaneous Urticaria

1200 mins

Learning Zone Homepage

Multiple Sclerosis (MS) Learning Zone

160 mins

Food Allergy_Selection of foods and allergies TEASER

Learning Zone Homepage

Food Allergy Learning Zone

280 mins

Learning Zone Homepage

Inflammatory Bowel Disease Learning Zone

100 mins

Learning Zone Homepage

Improving treatment options for childhood psoriasis

270 mins

Managing risk of recurrence in early breast cancer – what’s on the horizon?

Learning Zone

CDK4/6 inhibitors in breast cancer

199 mins

Learning Zone Homepage

Managing Osteoarthritis-associated Pain

265 mins

Learning Zone Homepage

Respiratory Care

530 mins

Learning Zone Homepage

Fibrinogen Deficiency in Bleeding Learning Zone

160 mins

Learning Zone Homepage

Idiopathic Pulmonary Fibrosis

140 mins

Oral Anticoagulation Reversal TEASER image

Learning Zone Homepage

Oral Anticoagulation Reversal Learning Zone

355 mins

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.